October 23, 2025 ⋅ 5 min reAd
Semaglutide Safety Information
Who it’s for
Semaglutide-based therapy may be prescribed for chronic weight management in appropriate patients as part of a broader program that includes nutrition and physical activity.
Who should not use
A licensed clinician must screen for contraindications and major risk factors. Patients should disclose full medical history, medications, and family history. If a patient has concerning symptoms (for example, a new neck lump, hoarseness, trouble swallowing, or shortness of breath), they should seek medical evaluation promptly.
Compounded disclosures
If the medication is compounded, disclose clearly: compounded drugs are not FDA-approved, and the FDA does not verify their safety, effectiveness, or quality before marketing.
Patients should also be warned not to combine semaglutide with other GLP-1/GIP medicines unless directed by a clinician, and that safety with other weight-loss products may not be established.
When to seek urgent care
List red-flag symptoms (severe/persistent vomiting, dehydration signs, severe abdominal pain, allergic reactions) and provide a clear emergency instruction.
How to get help
If medication is provided in a vial, patients must measure doses accurately. Confusion between measurement units is a known risk with compounded injectables. Patients should follow clinician/pharmacy instructions and contact the care team if uncertain.
